Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS Benefits From Focused Strategy, Novartis Looks To Vaccines; Abbott Tries To Educate U.S. Investors: Emerging Markets Earnings Roundup (Part 2)

This article was originally published in PharmAsia News

Executive Summary

Emerging markets remained a key focus of Big Pharma during first quarter earnings calls, with many highlighting exceptional growth in these markets, particularly China. Others talked at length about commercial strategy and sales force expansion, with some companies like Bristol-Myers Squibb Co. hyping the virtues of staying true to its innovative roots, while others like Novartis AG talked up the value of diversification. And Abbott Laboratories, in its continuing quest to "educate" U.S. investors about emerging markets, decided for a wholesale change in how it reports its business, although the initial reaction from at least one analyst might have caught the company off guard.
Advertisement

Related Content

Follow The CEO? Abbott Chief Chooses Diversified Products, Emerging Markets Over Rx Drugs As Company Splits In Two
Emerging Views On Emerging Markets: Bank of America Merrill Lynch Global Healthcare Conference
Are Emerging Markets Part Of Big Pharma's Core Business?
Merck Looks To Leverage "Next 10" For Growth: Emerging Markets Earnings Roundup (Part 4)
Pfizer Weighs Options For Future Of Established Products Business Unit As Revenues Show Strong Trends: Emerging Markets Earnings Roundup (Part 3)
Abbott, Eli Lilly, Novartis: Emerging Markets Earnings Round Up (Part 1)
Russia Pledges $3.9 Billion For Local Pharma Growth, As Big Pharma Scrambles To Set Up Shop
Novartis Edges Out BMS In Japan With First-line Indication Approval For Tasigna Ahead Of Sprycel
Big Brand Fights Come To India As Januvia, Galvus And Onglyza Vie For Market Share
Big Brand Fights Come To India As Januvia, Galvus And Onglyza Vie For Market Share
Advertisement
UsernamePublicRestriction

Register

SC078132

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel